Emmily Mourao

Mrs. Emmily Mourao

Instituto Nacional de Pesquisa da Amazonia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HMHamza Mechchate
Hamza Mechchate
ROREGIANE COSTA DE OLIVEIRA
REGIANE COSTA DE OLIVEIRA
IEImane Es-safi
Imane Es-safi
EMEmmily Mourao
Emmily Mourao
MBMohamed Bouhrim
Mohamed Bouhrim
AGAndriy Grafov
Andriy Grafov
Leukemia is a group of hematological neoplastic disorders linked to high mortality rates worldwide, but increasing resistance has led to the therapeutic failure of conventional chemotherapy. This study aimed to evaluate in vitro the antileukemic activity and potential mechanism of action of a polyphenolic extract obtained from the seeds of Coriandrum sativum L. (CSP). A methylthiazoletetrazolium assay was performed to assess the CSP cytotoxicity on chronic (K562) and acute (HL60) myeloid leukemia cell lines and on normal Vero cell line. CSP toxicity was also evaluated in vivo using the OECD 423 acute toxicity model on Swiss albino mice. The results demonstrated a remarkable antitumoral activity against K562 and HL60 cell lines (IC50 = 16.86 µM and 11.75 µM, respectively) although no cytotoxicity was observed for the Vero cells or mice. A silico study was performed on the following receptors that are highly implicated in the development of leukemia: ABL kinase, ABL1, BCL2, and FLT3. The molecular docking demonstrated a high affinity interaction between the principal CSP components and the receptors. Our findings demonstrated that CSP extract has remarkable antileukemic activity, which is mainly mediated by the flavonoids, catechins, and rutin, all of which showed the highest binding affinity for the targeted receptors. This study revealed a promising active compound alternative research-oriented biopharmacists to explore.

1 January 2025 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
KAKessia Caroline Souza Alves
Kessia Caroline Souza Alves
EMEmmily Mourao
Emmily Mourao
JMJoyce Marinho Melo
Joyce Marinho Melo
MAMaria Edilene Martins Almeida
Maria Edilene Martins Almeida
JOJuliana Gomes de Souza Oliveira
Juliana Gomes de Souza Oliveira
LMLuis André Mariuba
Luis André Mariuba
For decades, research and development toward malaria vaccine has prioritized infections caused by Plasmodium falciparum, since it is the species responsible for the most severe cases of malaria, which results in a comparatively smaller number of studies devoted to Plasmodium vivax. This disparity is due to complexities inherent in the biology of P. vivax, including the formation of hypnozoites in the pre-erythrocytic phase, difficulties in establishing robust in vitro culture systems, and the absence of fully representative experimental models. Among the antigens investigated for vaccine formulations, the Plasmodium vivax circumsporozoite surface protein (PvCSP) stands out for its immunogenic potential and the partial protection observed in preclinical studies. However, clinical trials with PvCSP-based vaccines have not yet demonstrated a consistent protective response. This review aims to show a historical overview of the studies that have evaluated the potential of vaccines based on the PvCSP protein, as well as to explore the innovative approaches that have been investigated in the last decade to overcome the challenges and advance the development of an effective vaccine against malaria caused by P. vivax.